<div id="readability-page-1"><p>Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 947,800 shares,  a growth of 28.0% from the November 30th total of 740,300 shares. Based on an average trading volume of 212,600 shares, the days-to-cover ratio is currently 4.5 days. Approximately 1.7% of the shares of the company are short sold.</p><div><p><span></span><span>Get <strong>Ovid Therapeutics</strong> alerts:</span></p></div><h2>Ovid Therapeutics Price Performance</h2><p>Shares of OVID stock traded down $0.02 during trading hours on Tuesday, reaching $0.93. The company had a trading volume of 195,703 shares, compared to its average volume of 377,271. The stock has a fifty day moving average of $1.11 and a 200-day moving average of $1.06. The company has a market capitalization of $66.30 million, a price-to-earnings ratio of -1.99 and a beta of 0.29. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.66 and a current ratio of 5.66. Ovid Therapeutics has a 12-month low of $0.68 and a 12-month high of $4.10. </p><p>Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.15 million.  On average, equities analysts anticipate that  Ovid Therapeutics will post -0.48 earnings per share for the current year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Separately, HC Wainwright  reaffirmed a &#34;buy&#34; rating and set a $3.00 target price on shares of Ovid Therapeutics in a report on Wednesday, December 4th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one  has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $4.04.</p><p><b>View Our Latest Analysis on OVID</b></p><h2>Institutional Investors Weigh In On Ovid Therapeutics</h2><p>Several institutional investors have recently modified their holdings of OVID. XTX Topco Ltd lifted its holdings in shares of  Ovid Therapeutics by 46.2% during the third quarter. XTX Topco Ltd now owns 38,230 shares of the company's stock worth $45,000 after purchasing an additional 12,076 shares during the period.  DCF Advisers LLC lifted its position in  Ovid Therapeutics by 111.6% during the second quarter. DCF Advisers LLC now owns 41,750 shares of the company's stock valued at $32,000 after buying an additional 22,020 shares in the last quarter.  FMR LLC raised its position in  Ovid Therapeutics by 1,907.4% in the third quarter. FMR LLC now owns 50,225 shares of the company's stock valued at $59,000 after purchasing an additional 47,723 shares during the period.  Verition Fund Management LLC purchased a new position in  Ovid Therapeutics in the 3rd quarter worth approximately $88,000.  Finally, Barclays PLC lifted its holdings in  Ovid Therapeutics by 311.2% in the 3rd quarter. Barclays PLC now owns 84,175 shares of the company's stock worth $98,000 after buying an additional 63,702 shares in the last quarter. 72.24% of the stock is owned by hedge funds and other institutional investors. </p><h2>About Ovid Therapeutics</h2> (Get Free Report)<p>Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.</p><h2>See Also</h2><ul><li>Five stocks we like better than Ovid Therapeutics</li><li>Which Wall Street Analysts are the Most Accurate?</li><li>3 Stocks Helping to Bring AI to Healthcare</li><li>The Risks of Owning Bonds</li><li>3 Stocks Ringing in The New Year With Large Buyback Announcements</li><li>How to Read Stock Charts for Beginners</li><li>Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ We recommended Palantir in 2021, now we’re recommending this... <span><span>(From Behind the Markets)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg0MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg0MQ"/></p><h2>Should you invest $1,000 in Ovid Therapeutics right now?</h2><p>Before you consider Ovid Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ovid Therapeutics wasn't on the list.</p><p>While Ovid Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OVID

<p>Ovid Therapeutics Inc. (NASDAQ:OVID) experienced a significant increase in short interest, rising 28.0% to 947,800 shares by December 15. The days-to-cover ratio stands at 4.5 days, with 1.7% of shares short sold. The stock traded down to $0.93, with a market cap of $66.30 million and a negative EPS of ($0.20). Analysts maintain a "Moderate Buy" consensus with a target price of $4.04. Institutional investors hold 72.24% of the stock, reflecting growing interest in the biopharmaceutical company focused on epilepsy treatments.</p>

Ovid Therapeutics Inc. (NASDAQ:OVID) Sees Significant Growth in Short Interest